Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 22, 2019
Pharmacy Choice - Pharmaceutical News - Grifols receives FDA approval of Erytra Eflexis, the latest advancement in scalable blood typing solutions - January 22, 2019

Pharmacy News Article

 1/8/19 - Grifols receives FDA approval of Erytra Eflexis, the latest advancement in scalable blood typing solutions

- Erytra Eflexis is a fully automated, benchtop analyzer that performs pretransfusion compatibility testing

- This system incorporates two laboratory configurations in a single instrument, providing laboratory technicians adaptable solutions for daily workloads

- Grifolsisa leader in innovative blood typing systems that support safer transfusions worldwide

BARCELONA, Spain, Jan. 8, 2019 /PRNewswire/ Grifols, a leading producer of plasma- derived medicines and recognized leader in transfusion medicine, has received U.S. Food and Drug Administration approval of Erytra Eflexis, a fully automated, benchtop analyzer. The system performs pretransfusion compatibility testing using DG Geltechnology.

Erytra Eflexis expands the Grifols' portfolio of blood typing solutions and can be used as a stand-alone system or in combination with other Grifols blood typing portfolio solutions. Erytra Eflexis facilitates multiple lab configurations and its ease of use requires minimal laboratory technician interaction.

"Grifols' dedication to developing and distributing improved diagnostic solutions has been exceptionally successful this year," said Carsten Schroeder, President of Grifols Commercial Diagnostic Division. "Erytra Eflexis marks our seventh FDA diagnostic approval so far in 2018, and it's the third approval for our expanding blood typing portfolio. And, feedback from the European medical community continues to be positive since receiving the CE Mark in June 2017."

Erytra Eflexis incorporates two lab configurations in a single instrument so laboratories can select the solution best suited to various workflow needs and capacities. This smart, flexible and intuitive system optimizes workflow efficiency and improves daily workloads, providing laboratories with a high level of flexibility and adaptability. It's designed for enhanced quality control to support improved patient care.

Interchangeable sample and reagent linear racks allow easy, continuous loading of cards, reagents and samples. A benchtop, compact model, Erytra Eflexisfeatures real random access with a capacity of up to 200 cards, 72 samples and 46 liquid reagents. The transparent casing provides a clear view of the simple internal organization and processes.

For more information about Grifols Diagnostic Solutions, visit diagnostic.grifols.com.

About Grifols

Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitalsand healthcare professionals with the tools, information and services they need to help them deliver expert medical care.

Grifols' three main divisions Bioscience, Diagnostic and Hospital develop, produce and market innovative products and services that are available in more than 100 countries.

With a network of approximately 250 plasma donation centers, Grifols is a leading producer of plasma-derived medicines used to treat rare, chronic and, at times, life- threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital Division provides intravenous (IV) therapies, clinical nutrition products and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.

Grifols is headquartered in Barcelona, Spain and has 20,000 employees in 30 countries.

In 2017, sales exceeded 4,300 million euros. Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ:GRFS).

For more information, visit grifols.com

Photo - https://mma.prnewswire.com/media/805120/Grifols-Erytra-Eflexis.jpg




Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jan 22: Medication Use During Pregnancy & Lactation
Last Chance
Jan 23: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Jan 24: COPD Update for Pharmacy Professionals
Jan 28: From Memory to Alzheimer’s - Supporting Memory With Lifestyle Medicine
Jan 29: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415